Comparison of the prevalence of major transfusion-transmitted infections among Iranian blood donors using confidential unit exclusion in an Iranian population

Authors

Azadeh OmidKhoda1, Ahmad Gharehbaghian2,*, Mostafa Jamali1, Naser AhmadBeigi1, Seyed Mahmoud Hashemi1, Abas Rahimi1, Masoud Soleimani1
1Iranian Blood Transfusion Organization (IBTO) Research Center, Tehran, IR Iran
2Iranian Blood Transfusion Organization Research Center, [email protected], Tehran, IR Iran
*Corresponding Author: Iranian Blood Transfusion Organization Research Center, [email protected], Tehran, IR Iran. Tel: +98-2188601573. Fax: +98-2188060717. Email: [email protected]

Hepatitis Monthly:Vol. 11, issue 1; 11-13
Published online:Jan 31, 2011
Article type:Research Article
Received:Oct 27, 2009
Accepted:Nov 16, 2010
How to Cite:OmidKhoda A, Gharehbaghian A, Jamali M, AhmadBeigi N, Hashemi S, et al. Comparison of the prevalence of major transfusion-transmitted infections among Iranian blood donors using confidential unit exclusion in an Iranian population. Hepat Mon. 2011;11(1):. doi:

Abstract

Background: Nucleic acid amplification testing is recommended for screening blood donations; however, they are not widely available in developing countries such as Iranian. Confidential unit exclusion (CUE) gives blood donors the opportunity to confidentially indicate whether their blood is or is not suitable for transfusion to others. Hoewever, its effectiveness in improving blood safety has recently been questioned by the blood banking community.
Objectives: The purpose of this study was to determine the efficacy of CUE in Iran.
Patients and Methods: Data on transfusion-transmitted disease markers (HBs Ag, HCV Ab, HIV Ab, RPR) were extracted from a database of voluntary blood donations in 2006 at the Tehran Blood Transfusion Center. The prevalence of markers were compared between CUE-positive ("should not use") and CUE-negative ("can be used") donations.
Results: CUE-positive donations had significantly higher risk of HBV and HCV markers (odds ratio (95% confidence interval): 7.5 (5.4-10.5) and 5.3 (2.5-11.3), respectively). No HIV or syphilis markers were detected in either group.
Conclusions: CUE is an effective option for identifying donors with increased risk of HBV and HCV markers.


 

  • Implication for Health policy/practice/research/medical education:
    The study discusses the prevalence of blood-born disorders among volunteer donors and the role of self-confidence exclusion in the improvement of health status of individual patients. Reading this article is recommended to the specialists in the field of transfusion medicine, epidemiologists, infection diseases, and health policy makers.
  • Please cite this paper as:
    Omid Khoda A, Gharehbaghian A , Jamali M, Ahmad Beigi N, Hashemi SM, Rahimi A, et al. Comparison the prevalence of the major transfusion-trans¬mitted infections in blood donors using confidential unit exclusion in Iranian population. Hepat Mon. 2011;11(1):11-13.

2011 Kowsar M.P.Co. All rights reserved.


Full Text

Full text is available in PDF

Copyright

© 2011, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

30
Nov
2011

Efficacy of the Confidential Unit Exclusion Option in Blood Donors in Tehran, Iran, Determined by Using the Nucleic Acid Testing Method in 2008 and 2009

Elham Farhadi,
Ahmad Gharehbaghian,
Gharib Karimi,
Shahram Samiee,
Farzaneh Tavasolli,
Yahya Salimi

Farhadi E, Gharehbaghian A, Karimi G, Samiee S, Tavasolli F, et al. Efficacy of the Confidential Unit Exclusion Option in Blood Donors in Tehran, Iran, Determined by Using the Nucleic Acid Testing Method in 2008 and 2009. Hepat Mon. 2011;11(11):. doi: https://doi.org/10.5812/kowsar.1735143X.778

23
Dec
2020
Efficacy of Blood Donor Selection: Comparing Sero-Prevalence of Transfusion-Transmissible Infections Among Eligible and High-Risk Behavior Deferred Donors in Iran

Efficacy of Blood Donor Selection: Comparing Sero-Prevalence of Transfusion-Transmissible Infections Among Eligible and High-Risk Behavior Deferred Donors in Iran

Sara Riyahi,
Sedigheh Amini-Kafiabad,
Daryoush Minai Tehrani,
Mahtab Maghsudlu,
Seyed Moayed Alavian

Riyahi S, Amini-Kafiabad S, Minai Tehrani D, Maghsudlu M, Alavian SM. Efficacy of Blood Donor Selection: Comparing Sero-Prevalence of Transfusion-Transmissible Infections Among Eligible and High-Risk Behavior Deferred Donors in Iran. Hepat Mon. 2020;20(11):e109451. doi: https://doi.org/10.5812/hepatmon.109451

24
Oct
2008

Prevalence of hepatitis C and its risk factors in blood donors at Shiraz transfusion center

Leila kasraian,
Alireza Tavasoli

kasraian L, Tavasoli A. Prevalence of hepatitis C and its risk factors in blood donors at Shiraz transfusion center. koomesh. 2008;10(1):e152213. doi:

9
Nov
2021
Prevalence of Transfusion Transmissible Infections Among Blood Donors in South Khorasan Province, Iran: An 11-Year Study

Prevalence of Transfusion Transmissible Infections Among Blood Donors in South Khorasan Province, Iran: An 11-Year Study

Behzad Mesbahzadeh,
Mohammad Reza Ameli,
Arman Ranjbar Moghadam,
Seyed Mehdi Sajjadi

Mesbahzadeh B, Ameli MR, Ranjbar Moghadam A, Sajjadi SM. Prevalence of Transfusion Transmissible Infections Among Blood Donors in South Khorasan Province, Iran: An 11-Year Study. Mod Care J. 2021;18(3):e118072. doi: https://doi.org/10.5812/modernc.118072

28
Mar
2016

Prevalence of hepatitis B, hepatitis C and HIV in blood donors in Semnan province (Iran) from 2011 to 2015

Marzie Rezaie,
Ali khaleghian

Rezaie M, khaleghian A. Prevalence of hepatitis B, hepatitis C and HIV in blood donors in Semnan province (Iran) from 2011 to 2015. koomesh. 2016;17(2):e151370. doi:

More by these authors

Azadeh OmidKhodaPubMedScholar
Ahmad GharehbaghianPubMedScholar
Mostafa JamaliPubMedScholar
Naser AhmadBeigiPubMedScholar
Seyed HashemiPubMedScholar
Abas RahimiPubMedScholar
Masoud SoleimaniPubMedScholar
Share
Cited by
Metrics